Thrombophilia and hypercoagulability

Medical Principles and Practice

Volumn 18, Issue 6, 2009, Pages 429-440

  Hassouna, Houria I ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Antiphospholipid syndrome; Hypercoagulability; Thrombophilia

Indexed keywords

BETA2 GLYCOPROTEIN 1; LUPUS ANTICOAGULANT; WARFARIN;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CASE REPORT; DOPPLER FLOWMETRY; FIBRIN CLOT; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; MALE; REVIEW; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOPHILIA; THROMBOPLASTIN TIME; VEIN OCCLUSION; VEIN THROMBOSIS;

BLOOD COAGULATION; HUMANS; THROMBOPHILIA; THROMBOSIS;

EID: 70349754156     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235891     Document Type: Review

References (72)

1. Dahlback B: Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112: 19-27.
2. Bowie EJW, Thompson JH, Pascuzzi CA, Owen CA: Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430.
3. Boey ML, Colaco CB, Gharavi AE: Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating anticoagulant. Br Med J 1983; 287: 1021-1023.
4. Asherton RA: A primary anti-phospholipid syndrome? J Rheumatol 1989; 16: 1742-1745.
5. Harris EN, Gharavi AE, Loizou S: Cross reactivity of antiphospholipid antibodies. J Clin Lab Immunol 1985; 2: 1211-1214.
6. Lopez-Soto A, Cervera R, Font J: Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidyl inositol and phosphatidyl serine in systemic lupus erythymatosus: prospective analysis in a series of 92 patients. Clin Exp Rheumatol 1997; 15: 143-149. (Pubitemid 27224649)
7. Gharavi A, Pierangeli S, Harris N: New developments in viral peptides and APL induction. J Autoimmun 2000; 15: 227-230. (Pubitemid 30707598)
8. Atkinson JP: Complement system on the attack in autoimmunity. J Clin Invest 2003; 112: 1639-1641.
9. Galli M, Luciani D, Bertolini G, Barbui T: Anti-beta-2 glycoprotein 1, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-2723. (Pubitemid 37248837)
10. Harris EN, Pierangeli SS: Primary, secondary and catastrophic antiphospholipid syndrome: what's in a name. Semin Thromb Hemost 2008; 34: 219-226.
11. Lockshin MD, Sammarito LR, Schwartzman S: Validation of the Sapporo criteria for the antiphospholipid syndrome - coming to grips with evidence and Thomas Bayes? Thromb Haemost 2006; 4: 295-306.
12. Branch DW, Khamashta MA: Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 2003; 101: 1333-1344.
13. Praprotnik S, Ferluga D, Vizjak A, Hvala A, Rozman B: Microthrombotic/microangiopathic manifestations of the antiphospholipid syndrome. Clin Rev Allergy Immunol 2009; 36: 109-125.
14. Egeberg O: Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530.
15. Marciniak E, Farley CH, DeSimone PA: Familial thrombosis due to antithrombin III deficiency. Blood 1974; 43: 219-231.
16. Rosenberg RD, Damus PS: The purification and mechanism of action of human anti-thrombin- heparin cofactor. J Biol Chem 1973; 248: 6490-6505.
17. Stenflo J: A new vitamin K-dependent protein: purification from bovine plasma and preliminary characterization. J Biol Chem 1976; 251: 355-363.
18. Kiesel W: Human protein C: isolation, characterization and mechanism of activation by α -thrombin. J Clin Invest 1979; 64: 761-769.
19. Martinoli JL, Stocker K: Fast functional protein C assay using Protac, a novel protein C activator. Thromb Res 1986; 43: 253-264.
20. Kisiel W, Choi E, Kondo S: Isolation of a protein C activator from southern copperhead venom. Biochem Biophys Res Commun 1987; 143: 917-922. (Pubitemid 17048357)
21. Kisiel W, Kondo S, Smith KJ, McMullen BA, Smith LF: Characterization of a protein C activator from Agkistrodon contortrix contortrix venom. J Biol Chem 1987; 262: 12607-12613.
22. Exner T, Vaasjoki R: Characterization and some properties of the protein C activator from Akistrodon contortrix contortrix venom. Thromb Haemost 1988; 59: 40-44.
23. Suzuki K, Stenflo J, Dahlback B, Teodorsson B: Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1983; 258: 1914-1920.
24. Walker FJ, Sexton PW, Esmon CT: The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta 1979; 571: 333-342.
25. Esmon CT: The regulation of natural antico-agulant pathways. Science 1987; 235: 1348.
26. Lu D, Kalafatis M, Mann KG, Long GL: Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87: 4708-4717. (Pubitemid 26162370)
27. Thorelli E, Kaufman RJ, Dahlback B: Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999; 93: 2552-2558. (Pubitemid 29181187)
28. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C: Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373. (Pubitemid 12235040)
29. Schwarz HP, Fisher M, Hopmeier P, Batard MA, Griffin JH: Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297-1300. (Pubitemid 15224546)
30. Comp PC, Nixon RR, Cooper MR, Esmon CT: Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-2088. (Pubitemid 15197352)
31. Walker FJ, Fay PJ: Regulation of blood co-agulation by the protein C system. FASEB J 1993; 6: 2561-2567.
32. Foster DC, Yoshitake S, Davie EW: The nucleotide sequence of the gene for human protein C. Proc Natl Acad Sci USA 1985; 82: 4673-4677.
33. Hassouna HI: Method and assay using inactivation of factors Va and VIIIa by activated protein C to diagnose thrombic disease or assay for protein C and kit therefor. US patent 5,051,357, September 24, 1991.
34. Hassouna HI: Laboratory evaluation of hemostatic disorders. Hematol Oncol Clin North Am 1993; 7: 1161-1249.
35. Hassouna H, Quinn C: Proteolysis of protein C in pooled normal plasma and purified protein C by activated protein C (APC). Biophys Chem 2002; 95: 109-124. (Pubitemid 34193083)
36. Bertina RM, Koeleman BPC, Koster T: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-79.
37. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008. (Pubitemid 23053939)
38. Girolami A, Vianello F: The significance or nonsignificance of the G to A 2010 prothrombin polymorphism. Clin Appl Thromb Hemost 2000; 6: 239-240. (Pubitemid 33143856)
39. Pabinger I, Schneider B: Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency: a cooperative retrospective study. Arterioscler Thromb Vasc Biol 1996; 16: 742-748. (Pubitemid 26179362)
40. Rosendaal FR: Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-619.
41. Bovill EG, Hasstedt SJ, Leppert MF, Long LL: Hereditary thrombophilia as a model for multigenic disease. Thromb Haemost 1999; 82: 662-666.
42. World Health Organization: Inherited Thrombophilia: Report of a Joint WHO/International Society of Thrombosis and Haemostasis (ISTH) Meeting. Geneva, World Health Organization, 1995.
43. Miletich J, Sherman L, Broze G: Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-996. (Pubitemid 17147955)
44. Martinelli I, Manucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, Paciaroni K, Leone G, Faioni E: Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-2358. (Pubitemid 28452977)
45. Brouwer JL, Lijfering WM, ten Kate MK, Kluin-Nelemans H, Veeger NJGM, van der Meer J: High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost 2009; 101: 93-99.
46. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG: Tissue factor activity in whole blood. Blood 2005; 105: 2764-2770. (Pubitemid 40446267)
47. Mackman N, Morissey JH, Fowler B, Edgington TS: Complete sequence of the human tissue factor gene, a highly regulated receptor that initiates the coagulation protease cascade. Biochemistry 1989; 28: 1755-1762. (Pubitemid 19072050)
48. Quien ET, Morales E, Cisar LA, Kim HC, Cimini C, Saidi P, Phillip CS: Plasma tissue factor antigen levels in capillary whole blood and venous blood: effect of tissue factor on prothrombin time. Am J Hematol 1997; 55: 193-198. (Pubitemid 27360055)
49. Chao TH, Li YH, Tsai WC, Chen JH, Liu PY, Tsai LM: Elevation of the soluble thrombo-modulin levels is associated with inflammation after percutaneous coronary interventions. Clin Cardiol 2006; 277: 407-410.
50. Whiteman T, Hassouna HI: Hypercoagulable states. Hematol Oncol Clin North Am 2000; 14:355-377.
51. Rosenberg R, Aird WC: Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340: 1555-1564.
52. Doolittle RF, Everse SJ, Spraggon G: Human fibrinogen: anticipating a 3-dimensional structure. FASEB J 1996; 10: 1464-1470.
53. Arkel YS, Bodner R, Ku DHW, Lake C, Siciliano F, Ogawa H, Yasue H, Oshima S, Okumura K, Matsuyama K, Obata K: Circadian variation of plasma fibrinopeptide A level in patients with variant angina. Circulation 1989; 80: 1617-1626. (Pubitemid 20031691)
54. Nakahara K, Kazahaya Y, Shintani Y, Yamazumi K, Eguchi Y, Koga S, Wada H, Matsuda M: Measurement of soluble fibrin monomer-fibrinogen complex in plasmas derived from patients with various underlying clinical situations. Thromb Haemost 2003; 89: 832-836. (Pubitemid 36603425)
55. Lam X: Thrombus precursor protein as a measure of prothrombotic activity in a patient with factor VIII inhibitor treated with activated prothombin complex concentrates. Thromb Hemost 1999; 82: 152-153.
56. Mosesson MW, Sienbenlist KR, Amrani DL, DiOrio JP: Identification of covalently linked trimeric and tetrameric crosslinked fibrin. Proc Natl Acad Sci USA 1989; 86: 113-117.
57. Palareti G, Legnani C, Cosmi B, Valdre L, Lunghi B, Bernardi F, Coccheri S: Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313-318. (Pubitemid 36899022)
58. Blann AD, Nadar SK, Lip GYH: The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166-2179. (Pubitemid 37522669)
59. Gokulakrishnan K, Deepa R, Mohan V, Gross MD: Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome: the Chennai Urban Rural Epidemiology Study. Metabolism 2006; 55: 237-242. (Pubitemid 43098993)
60. Hassouna HI: Blood stasis, thrombosis and fibrinolysis. Hematol Oncol Clin North Am 2000; 14:xvii-xxii.
61. Miranda AR, Hassouna HI: Mechanisms of thrombosis in spinal cord injury. Hematol Oncol Clin North Am 2000; 14: 401-416. (Pubitemid 30241187)
62. Li YH, Teng JK, Tsai WC, Tsai LM, Lin LJ, Guo HR, Chen JH: Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction. J Am Coll Cardiol 1999; 33: 1543-1548.
63. Chan MY, Andreotti F, Becker RC: Contemporary reviews in cardiovascular medicine: hypercoagulable states in cardiovascular disease. Circulation 2008; 118: 2286-2297.
64. Mannucci PM, Bauer KA, Santagostino E, Faioni E, Barzegar S, Coppola R, Rosenberg RD: Activation of the coagulation cascade after infusion of a factor IX concentrate in congenitally deficient patients. Blood 1994; 84: 1314-1319. (Pubitemid 24245901)
65. Bauer KA, Humphries S, Smillie B, Li L, Cooper JA, Barzegar S, Rosenberg RD, Miller GJ: Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations. Thromb Haemost 2000; 84: 396-400. (Pubitemid 30702235)
66. Bauer KA, Broekmans AW, Bertina RM, Conrad J, Horrellou MH, Samama MM, Rosenberg RD: Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood 1988; 71: 1418-1426.
67. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, Marinarini S, Finazzi G, Cerletti C, Barbui T: Polymorpho-nuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261-4266.
68. Furie KL, Rosenberg R, Thompson JL, Bauer K, Mohr JP, Rosner B, Sciacca R, Barzegar S, Thornell B, Costigan T, Kistler JP: Thrombin generation in non-cardioembolic stroke sub-types: the Hemostatic System Activation Study. Neurology 2004; 63: 777-784. (Pubitemid 39297634)
69. Barac A, Campia U, Panza JA: Methods for evaluating endothelial function in humans. Hypertension 2007; 49: 748-760. (Pubitemid 351664221)
70. Tzoulaki I, Murray GD, Price JF, Smith FB, Lee AJ, Rumley A, Lowe GD, Fowkes FG: Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. Am J Epidemiol 2006; 163: 334-341. (Pubitemid 43238427)
71. Koga S: A novel molecular marker for thrombus formation and life prognosis: clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex. Rinsho Byori 2004; 52: 355-361.
72. Mega JL, Morrow DA, de Lemos JA, Mohanavelu S, Cannon CP, Sabatine MS: Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. J Am Coll Cardiol 2008; 51: 2422-2429. (Pubitemid 351833103)